Vasopeptidase inhibitors: an emerging class of cardiovascular drugs (Q34175462)

31 July 2017

1 reference

title

Vasopeptidase inhibitors: an emerging class of cardiovascular drugs (English)

1 reference

31 July 2017

1 reference

Bralet J

1

1 reference

31 July 2017

Schwartz JC

series ordinal

2

1 reference

31 July 2017

publication date

1 March 2001

1 reference

Trends in Pharmacological Sciences

31 July 2017

published in

1 reference

31 July 2017

volume

22

1 reference

31 July 2017

issue

3

1 reference

31 July 2017

page(s)

106-109

1 reference

Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901644-8

7 January 2021

In vitro and in vivo inhibition of the 2 active sites of ACE by omapatrilat, a vasopeptidase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901644-8

7 January 2021

Protection of atrial natriuretic factor against degradation: diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3.4.24.11) by acetorphan

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901644-8

7 January 2021

Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901644-8

7 January 2021

Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901644-8

7 January 2021

Emerging treatments for hypertension: potential role for vasopeptidase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901644-8

7 January 2021

Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901644-8

7 January 2021

Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901644-8

7 January 2021

Effect of long-term therapy with fasidotril, a mixed inhibitor of neprilysin and angiotensin-converting enzyme (ACE), on survival of rats after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901644-8

7 January 2021

The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901644-8

7 January 2021

Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901644-8

7 January 2021

A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. ecadotril pilot safety study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901644-8

7 January 2021

Plasma bradykinin in angio-oedema.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901644-8

7 January 2021

Vasopeptidase inhibition and angio-oedema

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901644-8

7 January 2021

Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901644-8

7 January 2021

The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901644-8

7 January 2021

Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901644-8

7 January 2021

Dual mechanism of angiotensin II inhibits ANP-induced mesangial cGMP accumulation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2901644-8

7 January 2021

10.1016/S0165-6147(00)01644-8

Identifiers

DOI

1 reference

31 July 2017

1 reference